Compare Otis Worldwide Corp (OTIS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs TG Therapeutics Inc — how do they compare? Otis Worldwide Corp trades at $69.36 (market cap $26.67B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Otis Worldwide Corp is far larger — about 3.1× TG Therapeutics Inc's market cap, and Otis Worldwide Corp pays a 2.51% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| OTIS | TGTX | |
|---|---|---|
Market Cap | $26.67B | $8.53B |
Sector | Industrials | Health |
52-Week High | $93.62 | $59.06 |
52-Week Low | $69.30 | $26.94 |
Enterprise Value | $34.70B | $8.74B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide (OTIS) trades at $70.06, down 1.61% on the day, amid a bearish technical signal and recent earnings misses. The stock shows a P/E of 18.01 and P/S of 1.83, with strong cash flow from operations of $1.60B in 2025 but a negative net cash flow of -$1.22B. Recent news includes a dividend declaration and new contracts in China, while technical indicators highlight support near $70 and an oversold RSI.
The outlook is mixed: analyst consensus is a Buy with a $92.50 price target, implying upside, but risks include high debt-to-asset ratio of 75.54% and margin pressure from labor costs. Service segment growth offers stability, yet weak new equipment demand and guidance cuts temper near-term optimism.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
